Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas

Zhichao Tian and Weitao Yao *

Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

Taxanes (paclitaxel and docetaxel) play an important role in the treatment of advanced sarcomas. Albumin-bound paclitaxel (nab-paclitaxel) is a new kind of taxane and has many advantages compared with paclitaxel and docetaxel. Nab-paclitaxel is currently approved for the treatment of advanced breast, non-small cell lung, and pancreatic cancers. However, the efficacy of nab-paclitaxel in sarcomas has not been reviewed. In this review, we first compare the similarities and differences among nab-paclitaxel, paclitaxel, and docetaxel and then summarize the efficacy of nab-paclitaxel against various non-sarcoma malignancies based on clinical trials with reported results. The efficacy and clinical research progress on nab-paclitaxel in sarcomas are also summarized. This review will serve as a good reference for the application of nab-paclitaxel in clinical sarcoma treatment studies and the design of clinical trials.

Keywords: albumin-bound paclitaxel, taxanes, sarcoma, breast cancer, lung cancer, pancreatic cancer

INTRODUCTION

Sarcomas (sarcomas in this review refer only to bone and soft tissue sarcomas, excluding gastrointestinal stromal tumors and Kaposi sarcoma) are malignant tumors derived from mesenchymal tissue (1). Sarcomas have low incidence, accounting for only about 2% of all newly diagnosed malignancies in humans each year (1, 2), yielding approximately 200,000 new cases (3, 4). A small number of these patients have metastases at initial diagnosis. Approximately 50% of newly diagnosed nonmetastatic cases eventually progress to an advanced stage (2, 4–6). The systemic treatment for advanced sarcomas is the same as that for other malignancies, including chemotherapy, targeted therapy, and immunotherapy (1, 7).

As chemotherapy drugs, paclitaxel and docetaxel play an important role in the treatment of advanced sarcomas (7–12). Paclitaxel and docetaxel are taxanes (13). Taxanes represent an important class of antineoplastic agents that interfere with microtubule function, leading to altered mitosis and cellular death in vitro (14); in vivo, intratumoral concentrations of taxanes cause cell death due to chromosome missaggregation in multipolar spindles (15). Paclitaxel was originally extracted from the Pacific yew tree, a small slow-growing evergreen, coniferous tree (16). Owing to the initial scarcity of paclitaxel, docetaxel, a semisynthetic analog of paclitaxel produced
from the needles of the European yew tree, was developed (17, 18). Docetaxel differs from paclitaxel in its chemical structure in two positions (19). These small alterations make docetaxel different from paclitaxel in terms of water solubility, cellular effects, pharmacology, and other aspects (19–22) (Table 1).

Paclitaxel is currently one of the widely used antineoplastic agents with broad activity in several cancers, including breast cancer, ovarian cancer, endometrial cancer, squamous cell carcinoma, adenocarcinoma, non-small cell lung cancer (NSCLC), bladder cancer, cervical carcinoma, and esophageal cancer (35, 36). Paclitaxel is also used in the treatment of some sarcomas (8), especially angiosarcoma (11, 37). Docetaxel is a widely prescribed antineoplastic agent for a broad range of malignancies including breast cancer, lung cancer, head/neck cancer, prostate cancer, and gastric cancer (18, 21, 29, 38). The efficacy of docetaxel-based chemotherapy in the treatment of soft tissue sarcomas is comparable to that of first-line treatment with doxorubicin, but is considered inferior to doxorubicin chemotherapy because of its toxicity and administration complexity (39). Docetaxel-based chemotherapy is also considered a second-line treatment for advanced osteosarcoma (40). Nevertheless, paclitaxel and docetaxel have several clinical problems, including poor drug solubility and serious dose-limiting toxicities such as peripheral sensory neuropathy, myelosuppression, and allergic reactions. A number of these clinical problems have been associated with the solvents used for diluting these antineoplastic agents: Cremophor EL for paclitaxel and polysorbate 80 for docetaxel (23, 29, 41–43).

To overcome the clinical problems associated with the solvents used for diluting paclitaxel and docetaxel, albumin-bound paclitaxel (nab-paclitaxel) was developed (44). Nab-paclitaxel is an albumin-bound, 130-nm particle size formulation of paclitaxel that is devoid of any solvents or ethanol (14, 44). The lyophilized formulation, comprised of albumin and paclitaxel, is reconstituted in 0.9% NaCl to form a colloidal suspension (45). Compared with paclitaxel, despite having the same active ingredient (paclitaxel), the two different formulations exhibit unique efficacy and safety profiles (14, 30).

The development of albumin-bound nanotechnology as a delivery system for paclitaxel neutralized its hydrophobicity and provided better pharmacokinetic and pharmacodynamic characteristics (45, 46). Nab-paclitaxel showed increased endothelial cell transport, intratumor paclitaxel concentrations, and antitumor activity compared with cremophor-based paclitaxel (31, 44) (Table 1). To date, nab-paclitaxel has been indicated for the treatment of metastatic breast cancer, locally advanced or metastatic NSCLC, and metastatic pancreatic cancer in the USA (47). It also showed promising efficacy in many other solid tumors (48–50). Currently, a number of clinical trials on the efficacy of nab-paclitaxel in various malignancies are being conducted (https://clinicaltrials.gov). The available evidence shows that the efficacy and safety of nab-paclitaxel are superior to those of paclitaxel and docetaxel in a variety of malignancies (22, 51–53). Studies have also confirmed the effectiveness of nab-paclitaxel in the treatment of sarcomas (54–57). However, it is not clear whether this formulation is more effective than

---

**TABLE 1 | Comparison of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) with solvent-based paclitaxel and docetaxel.**

| Launch date | Structure | Solubilizer | Infusion time (min) | Corticosteroid premedication | Indications | Differences in patients of different ages | Preclinical studies | Prices |
|-------------|-----------|-------------|---------------------|-----------------------------|-------------|---------------------------------|-------------------|--------|
| Nab-paclitaxel | 2005 | Six or seven paclitaxel molecules bound non-covalently to an albumin molecule. | 20–30 | No | Breast cancer, lung cancer, and pancreatic cancer. | No differences were noted for pharmacodynamic variables (grade 3 toxicity, dose reductions, or dose omissions) based on age. It is well-tolerated across all age groups. | Compared with Cremophor EL-paclitaxel, nab-paclitaxel was associated with faster and deeper tissue penetration, shorter duration of high systemic exposure, and slower elimination of paclitaxel. | Significantly higher than docetaxel and solvent-based paclitaxel. |
| Docetaxel | 1996 | Nanoparticle albumin | 60 | Yes | Breast cancer, lung cancer, prostate cancer, gastric cancer, and head/neck cancer. | Showing lower docetaxel clearance in elderly patients than in younger patients. | Docetaxel exhibited more potent cytotoxicity against different tumors than paclitaxel both in vitro and in vivo. As for tubulin promotion and blocking depolymerization, docetaxel, is about five-fold more potent than paclitaxel. | Significantly lower than nab-paclitaxel, similar with solvent-based paclitaxel. |
| Solvent-based paclitaxel | 1992 | Polysorbate | 120–180 | Yes | | | | |
| Reference | | | | | | | | |

(23, 24)
(25)
(26–28)
(29–31)
(32–34)
conventional paclitaxel and docetaxel. In this review, we first considered the efficacy of nab-paclitaxel in the treatment of various non-sarcoma malignancies, and then focused on related studies of nab-paclitaxel in the treatment of sarcomas, with the aim of providing a reference to establish a clinical study design and to support clinical treatment of sarcomas.

Efficacy of Nab-Paclitaxel in Non-Sarcoma Malignancies

To fully evaluate the efficacy of nab-paclitaxel in the treatment of malignancies, systematic hand and online searches were conducted. The inclusion criteria for literature and clinical trials were as follows: 1) published in 2011 and later; 2) prospective phase II or III clinical trials; 3) trials of nab-paclitaxel monotherapy or combination therapy of malignancies; 4) trials with a registration number; and 5) trials with complete data published in open-access journals. The retrieved clinical trials and literature were classified according to the histopathological type.

Breast Cancer

Breast cancer was the first indication for which nab-paclitaxel was approved by the US Food and Drug Administration (FDA). The results of the first phase III trial in women with metastatic breast cancer showed that nab-paclitaxel demonstrated significantly higher response rates than standard paclitaxel (33% vs. 19%, respectively) and significantly longer progression-free survival (23.0 vs. 16.9 weeks, respectively) (58). This led to FDA approval of nab-paclitaxel in 2005 for second-line and above-line treatment of metastatic breast cancer. Since then, nab-paclitaxel has been widely studied in breast cancer, including attempts to use this formulation as a first-line treatment for metastatic breast cancer. However, these studies have not yielded sufficiently positive results to enable replacement of traditional first-line treatment (59–61). In a multicenter, randomized, comparative phase III study reported in 2018, atezolizumab plus nab-paclitaxel treatment prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and the programmed death ligand 1-positive subgroup (62). This led to FDA approval of nab-paclitaxel in combination with atezolizumab for first-line treatment of metastatic breast cancer in 2019.

Several recent clinical trials have shown that nab-paclitaxel is effective for the treatment of non-metastatic breast cancer in the neoadjuvant setting. Nab-paclitaxel improved the pathological complete response rate and event-free survival compared with traditional taxanes, and with acceptable toxicities (63). Current studies of nab-paclitaxel in breast cancer have focused on dose adjustment and combination regimens with other drugs (64–68). In conclusion, the application of nab-paclitaxel in breast cancer has gradually evolved from a single drug to combinations with other chemotherapy drugs and/or with immunotherapy. Nab-paclitaxel is now a basic drug in the treatment of breast cancer. With the invention and application of new anti-tumor drugs, the combination of nab-paclitaxel with other drugs, and different application scenarios in the treatment of breast cancer, the role of nab-paclitaxel will be further studied.

Lung Cancer

The results of a multicenter, randomized, controlled phase III clinical trial showed that nab-paclitaxel demonstrated a significantly higher objective response rate than solvent-based paclitaxel (33% vs. 25%) as first-line therapy in patients with advanced NSCLC (43). This led to FDA approval of nab-paclitaxel in combination with carboplatin as first-line treatment for advanced NSCLC in 2012. Since then, nab-paclitaxel has been widely studied in lung cancer. Subsequent clinical trials demonstrated the good activity of nab-paclitaxel combined with carboplatin in different patients with advanced NSCLC (69–72); however, nab-paclitaxel-based therapy had unsatisfactory efficacy in advanced small cell lung cancer (73, 74). Other clinical trials have shown that nab-paclitaxel-based chemotherapy worked as well as, or better than, other conventional drugs and regimens in advanced NSCLC (75–78). Recent clinical trial results show that nab-paclitaxel-based chemoradiotherapy has promising efficacy in the treatment of locally advanced NSCLC (79–81). Furthermore, the combination of nab-paclitaxel-based chemotherapy and immunotherapy can also achieve good efficacy (82–85). In conclusion, the clinical study of nab-paclitaxel in lung cancer has deepened our understanding of the treatment of advanced NSCLC patients who failed multi-line treatment by showing efficacy in multi-drug combination therapy, first-line, or neoadjuvant therapy in different subgroups. Clinical studies of nab-paclitaxel in lung cancer will become increasingly detailed and complex.

Pancreatic Cancer

The results of an international, multicenter, open label, randomized phase III study showed that treating metastatic pancreatic cancer patients with gemcitabine plus nab-paclitaxel (GnP) as first-line therapy resulted in a significantly higher median overall survival time than treatment with gemcitabine alone (8.5 vs. 6.7 months) (86). This led to FDA approval of nab-paclitaxel in combination with gemcitabine for first-line treatment of metastatic pancreatic adenocarcinoma in 2013. Since then, nab-paclitaxel has been widely studied for treating pancreatic cancer. These clinical trials and studies can be grouped into four categories: 1. Continued testing of GnP in different groups of patients with advanced pancreatic cancer, such as elderly patients and patients with poor physical performance (87–89); 2. Comparing the efficacy and safety of GnP with FOLFIRINOX (a conventional chemotherapy regimen) for pancreatic cancer (90–93); 3. Testing new multidrug combination regimens based on nab-paclitaxel (94–97); and 4. Preoperative adjuvant therapy in patients with locally advanced pancreatic cancer (98–100). In conclusion, the research
and application of nab-paclitaxel in pancreatic cancer are also a complex process from single to multi-drug combination therapy, from an ordinary to a special patient group, and from advanced first-line therapy to neoadjuvant therapy. According to various trial results, nab-paclitaxel has clear efficacy in the treatment of pancreatic cancer and has been considered a basic drug for adjuvant chemotherapy in this disease.

**Other Cancers**

As the price of nab-paclitaxel has decreased, the numbers of studies and trials on this agent in various cancers have increased significantly. At present, clinical trial results have shown that nab-paclitaxel has promising efficacy in gastric cancer, melanoma, gynecological malignancy, urothelial carcinoma, head and neck squamous cell carcinoma, biliary tract carcinoma, and nasopharyngeal carcinoma (50, 52, 101-104). The research and application of nab-paclitaxel in every kind of malignant tumor have gradually evolved toward the direction of combined and perioperative treatment, similar with its path in breast cancer, lung cancer, and pancreatic cancer (105-108). It is believed that, with further research, the status of nab-paclitaxel in various malignant tumors will gradually be equal to or even exceed that of traditional taxanes.

**Efficacy of Traditional Taxanes and Nab-Paclitaxel in Sarcomas**

**Efficacy of Traditional Taxanes in Sarcomas**

Taxanes are one of the important class of drugs in the treatment of sarcomas and are recommended as systemic chemotherapy drugs in the National Comprehensive Cancer Network guidelines for the treatment of sarcomas (109, 110). Recent data demonstrate that paclitaxel causes cell death due to chromosome missegregation on multipolar spindles (15). As the first taxanes, paclitaxel was proved to be ineffective in most soft tissue sarcomas, except angiosarcoma, in the 1990s (111). At present, paclitaxel is the first choice of chemotherapy for vasogenic malignancies (112, 113). With the application of targeted drugs in the treatment of sarcoma, the combination of paclitaxel and targeted drugs also shows promising activity (114). However, because of the simultaneous use of steroids, paclitaxel is obviously not suitable for use in combination with immunotherapeutic drugs.

As described earlier in this review, docetaxel, an improved and invented drug based on paclitaxel, is as effective as or better than paclitaxel in a variety of malignancies (Table 1) (19). Therefore, researchers initially concluded that the drug should also be more effective in sarcoma (17). However, the results of initial clinical trial have shown that docetaxel monotherapy has limited activity in sarcoma (115). Fortunately, subsequent clinical trials have shown that gemcitabine in combination with docetaxel is more effective (116, 117). This has led to extensive research and application of docetaxel and gemcitabine combination therapy in sarcomas. Currently, gemcitabine plus docetaxel is considered to have similar efficacy to doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (39). It is important to note that docetaxel plus gemcitabine combined with pazopanib is too toxic to be used. This has limited the application of this approach in the era of targeted therapy (118). In addition, docetaxel is also clearly not suitable for use in combination with immunotherapy drugs, since steroid use is also required.

**Efficacy of Nab-Paclitaxel in Sarcomas**

As a new and improved taxane chemotherapeutic drug, nab-paclitaxel has many advantages compared with paclitaxel and docetaxel (Table 1) (46). Like other drugs, the inhibitory effect of paclitaxel on tumor tissue is dose-dependent (15). Mechanistically, because it is less toxic and more penetrating, a higher tumor/plasma paclitaxel drug ratio in favor of nab-paclitaxel was observed (119). Because secreted protein acidic and rich in cysteine (SPARC) shows high binding affinity to albumin, a study has proved that pediatric sarcoma xenografts expressing SPARC would show enhanced uptake and accumulation of nab-paclitaxel (120). We therefore infer that nab-paclitaxel is likely to be more effective in sarcomas. However, as a new taxane drug, nab-paclitaxel has not been studied extensively in sarcomas. We systematically searched all relevant literature on the treatment of bone and soft tissue sarcomas with nab-paclitaxel, and the results are shown in Table 2. Current evidence shows that nab-paclitaxel has promising effects in the treatment of angiosarcoma, epithelioid sarcoma, leiomyosarcoma, and other subtypes of soft tissue sarcomas (Table 2). GnP showed mild activity in Ewing sarcoma (Table 2). However, the evidence level in these studies was not high. Compared with research on nab-paclitaxel in other malignant tumors and that on solvent-based paclitaxel in sarcomas, research on nab-paclitaxel in sarcomas is in its infancy.

**DISCUSSION**

In this review, we first determined the similarities and differences between nab-paclitaxel and other taxanes. We found that nab-paclitaxel has many advantages over traditional solvent-based taxanes in terms of structure and performance. We then summarized the therapeutic efficacy and clinical trial process of nab-paclitaxel in non-sarcoma malignancies. The application of nab-paclitaxel in various malignant tumors is a simple, but complex, process. Finally, we reviewed the application of traditional taxanes and nab-paclitaxel in treating sarcomas. At present, research on nab-paclitaxel in sarcomas is in its infancy. Current evidence shows that nab-paclitaxel may have better activity than traditional taxanes in some subtypes, such as angiosarcoma, epithelioid sarcoma, and leiomyosarcoma.
Based on the above review, we believe that the use of nab-paclitaxel in treating sarcomas is worthy of further study. These studies can be conducted in at least four different directions (Figure 1). 1) Sarcomas are divided into dozens of histological subtypes, and each subtype has a different sensitivity to taxanes. Therefore, the efficacy of nab-paclitaxel therapy should be evaluated for each subtype. 2) Combined application of nab-paclitaxel with other drugs (such as chemotherapy drugs, targeted drugs, and immunotherapy drugs), or radiotherapy and interventional therapy, should be studied further. For example, traditional taxanes cannot be effectively combined with immunotherapy because they require concurrent administration of steroids. However, studies have shown that nab-paclitaxel can regulate the immune microenvironment and sensitize cancers to immunotherapy (128–130). This suggests that nab-paclitaxel combined with immunotherapy for sarcomas may have a better curative effect. 3) Expanding the application of nab-paclitaxel to patients of different ages and patients with poor physical fitness should be explored. Compared with traditional taxanes, nab-paclitaxel has fewer toxic side effects and lower requirements for infusion conditions. Thus, it may have significant advantages in both young and elderly patients, or those with poor physical fitness. 4) Expand the application of nab-paclitaxel to different application scenarios of sarcoma treatment, such as neoadjuvant therapy and first-line treatment of advanced cancer patients. Over the past decade, the main reason for restricting the wide use of nab-paclitaxel has been its high price. At present, nab-

### TABLE 2 | Studies on the treatment of sarcomas with nanoparticle albumin-bound paclitaxel (nab-paclitaxel).

| Publication year | Research type | Research content | Conclusions | Reference |
|------------------|---------------|------------------|-------------|-----------|
| 2014             | Preclinical study | Preclinical evaluation of nab-paclitaxel in an Ewing sarcoma xenograft and an osteosarcoma model. | Observed growth inhibition and improved survival with nab-paclitaxel in an Ewing sarcoma xenograft; activity was additive with gemcitabine in an osteosarcoma model. | (121) |
| 2016             | Case report    | Reported a patient with angiosarcoma of the thoracic wall who responded well to nab-paclitaxel. | After 4 courses of chemotherapy, the tumors regressed remarkably. Nab-paclitaxel may be an effective treatment option for recurrent or metastatic angiosarcoma. | (122) |
| 2017             | Case report    | Reported a patient with cardiac angiosarcoma associated with disseminated intravascular coagulation who was successfully treated with nab-paclitaxel. | This report suggests the potential utility of nab-paclitaxel for angiosarcoma. | (123) |
| 2018             | Retrospective study |Reviewed the records of sixteen relapsed/refractory sarcoma patients who received gemcitabine/nab-paclitaxel. | Gemcitabine/nab-paclitaxel is a relatively safe regimen with mainly hematologic toxicities. It offers a well-tolerated, palliative option providing clinical benefit in a subset of patients. | (56) |
| 2018             | Phase I study | Sixty-four patients with recurrent/refractory extracranial solid tumours received nab-paclitaxel on days 1, 8, and 15 every 4 weeks at 120, 150, 210, 240, or 270 mg/m² to establish the maximum tolerated dose and recommended phase II dose. | Nab-paclitaxel 240 mg/m² qw 3/4 (nearly double the adult recommended mono-therapy dose for this schedule in metastatic breast cancer) was selected as the recommended phase II dose based on the tolerability profile, pharmacokinetics, and antitumor activity. | (54) |
| 2019             | Preclinical study | Determined the efficacy of nab-paclitaxel in combination with gemcitabine, compared to conventional drugs, such as docetaxel, gemcitabine combined with docetaxel on an undifferentiated/unclassified soft-tissue sarcoma from a stripped muscle implanted in the right biceps femoris muscle of nude mice to establish a patient-derived orthotopic xenograft model. | The results suggested that the combination of gemcitabine and nab-paclitaxel could be a promising therapeutic strategy for undifferentiated/unclassified soft-tissue sarcomas. | (57) |
| 2020             | Phase II study |Forty-two paediatric patients with recurrent or refractory Ewing sarcoma, neuroblastoma, or rhabdomyosarcoma received 240 mg/m² nab-paclitaxel on days 1, 8, and 15 of each 28-day cycle. The primary end-point was the overall response rate. | In this phase II study, limited activity was observed; however, the safety of nab-paclitaxel in pediatric patients was confirmed. | (124) |
| 2020             | Phase II study |Using a Simon’s two-stage design to identify a response rate of ≥ 35%, eleven patients with relapsed Ewing sarcoma received nab-paclitaxel 125 mg/m² followed by gemcitabine 1000 mg/m² i.v. on days 1, 8, and 15 of four-week cycles. Immunohistochemical analysis of archival tissue was performed to identify possible biomarkers of response. | In patients with heavily pretreated Ewing sarcoma, the confirmed response rate of 9% was similar with multi-institutional studies of gemcitabine and docetaxel. | (125) |
| 2020             | Retrospective study |The clinical data of seventeen sarcoma patients who received nab-paclitaxel/gemcitabine chemotherapy between January 2019 and February 2020 were retrospectively analysed. All these patients were treated with nab-paclitaxel/gemcitabine only after doxorubicin-based chemotherapy had failed. | Nab-paclitaxel/gemcitabine combination chemotherapy is comparatively effective in the treatment of soft tissue sarcoma, demonstrates low toxicity, and is worthy of further study. | (126) |
| 2021             | Case report    |Reported a pancreatic leiomyosarcoma patient who was successfully treated with nab-paclitaxel and gemcitabine. | Gemcitabine plus nab-paclitaxel therapy might be the first choice for soft-tissue sarcoma and leiomyosarcoma. | (127) |
Paclitaxel has successfully entered the list of essential drugs in China’s national medical insurance system, and its price has been greatly reduced. This indicates that the application and research of nab-paclitaxel in various malignant tumors, including sarcomas, will expand.

In conclusion, nab-paclitaxel has been shown to have better activity than paclitaxel and docetaxel in many types of malignant tumors. Although research on its efficacy in sarcomas is in its infancy, it has been shown to have promising efficacy in some sarcoma subtypes. Overall, nab-paclitaxel is expected to become one of the important basic drugs in the field of sarcoma treatment.

**AUTHOR CONTRIBUTIONS**
All authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication.

**REFERENCES**
1. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* (2018) 16:536–63. doi: 10.6004/jnccn.2018.0025
2. Sarcoma Committee of Chinese Anti-Cancer Association and Chinese Society of Clinical Oncology. Chinese Expert Consensus on Diagnosis and Treatment of Soft Tissue Sarcomas (Version 2015). *Zhonghua Zhong Liu Za Zhi* (2016) 38:310–20. doi: 10.3760/cma.j.issn.0253-3766.2016.04.013
3. Cipriano CA, Jang E, Tyler W. Sarcoma Surveillance: A Review of Current Evidence and Guidelines. *J Am Acad Orthop Surg* (2020) 28:145–56. doi: 10.5435/JAAOS-D-19-00002
4. Osasan S, Zhang M, Shen F, Paul PJ, Persad S, Sergi C. Osteogenic Sarcoma: A 21st Century Review. *Anticancer Res* (2016) 36:4391–8. doi: 10.21873/anticancer.10982
5. Ritter J, Bielack SS. Osteosarcoma. *Ann Oncol* (2010) 21:320–5. doi: 10.1093/annonc/mdq276
6. Bosma SE, Ayu O, Fiocco M, Gelderblom H, Dijkstra PDS. Prognostic Factors for Survival in Ewing Sarcoma: A Systematic Review. *Surg Oncol* (2018) 27:603–10. doi: 10.1016/j.suronc.2018.07.016
7. Singhri EK, Moore DC, Muslimani A. Metastatic Soft Tissue Sarcomas: A Review Of Treatment and New Pharmacotherapies. *P T* (2018) 43:410–29.
8. Nagar SP, Mytelka DS, Candrilli SD, D’Yachkova Y, Lorenzo M, Kasper B, et al. Treatment Patterns and Survival Among Adult Patients With Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France. *Sarcoma* (2018) 2018:5467057. doi: 10.1155/2018/5467057
9. Villalobos VM, Byfield SD, Ghate SR, Adenre O. A Retrospective Cohort Study of Treatment Patterns Among Patients With Metastatic Soft Tissue Sarcoma in the US. *Clin Sarcoma Res* (2017) 7:18. doi: 10.1186/s13569-017-0084-4
10. Maki. Gemcitabine RG. And Docetaxel in Metastatic Sarcoma: Past, Present, and Future. *Oncologist* (2007) 12:999–1006. doi: 10.1634/theoncologist.12-8-999
11. Penel N, Lansiaux A, Adenis A. Angiosarcomas and Taxanes. *Curr Treat Options Oncol* (2007) 8:428–34. doi: 10.1007/s11864-007-0042-0
12. Kim JH, Park HS, Heo SJ, Kim SK, Han JW, Shin KH, et al. Differences in the Efficacies of Paclitaxel and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma. Oncology (2019) 96:59–69. doi: 10.1159/000492597

13. Ojima I, Lichtenhall B, Lee S, Wang C, Wang X. Taxane Anticancer Agents: A Patent Perspective. Expert Opin Ther Pat (2016) 26:1–20. doi: 10.1517/13543776.2016.111872

14. Yared JA, Tkaczuk KH. Update on Taxane Development: New Analogs and New Formulations. Drug Des Devel Ther (2012) 6:731–84. doi: 10.2147/DDDT.S28997

15. Weaver BA. How Taxol/paclitaxel Kills Cancer Cells. Mol Biol Cell (2014) 25:2677–81. doi: 10.1091/mbc.E14-04-0916

16. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant Antitumor Agents: Structure of Taxol, a Novel Antileukemic and Antitumor Agent From Taxus Brevifolia. J Am Chem Soc (1971) 93:2335–7. doi: 10.1021/ja00738a045

17. Verweij J. Docetaxel: An Interesting New Drug for the Treatment of Head and Neck Cancers and Soft Tissue Sarcomas. Anticancer Drugs (1995) 6:19–24. doi: 10.1097/00001813-199507000-00004

18. Zhao P, Astruc D. Docetaxel Nanotechnology in Anticancer Therapy. Chem Med Chem (2012) 7:952–70. doi: 10.1002/cmdc.201200052

19. de Weger VA, Beijnen JH, Schellens JH. Cellular and Clinical Pharmacology of the Taxanes Docetaxel and Paclitaxel—A Review. Anticancer Drugs (2014) 25:488–94. doi: 10.1097/CAD.0000000000000093

20. Andriguetti NB, Raymundo S, Antunes MV, Perassolo MS, Verza SG, Suyенega ES, et al. Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel. Curr Med Chem (2017) 24:3559–82. doi: 10.2174/0929867X246617063093445

21. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for Treatment of Solid Tumours: A Systematic Review of Clinical Data. Lancet Oncol (2005) 6:229–39. doi: 10.1016/s1470-2045(05)70094-2

22. Lee H, Park S, Kang JE, Lee HM, Kim SA, Rhie SJ. Efficacy and Safety of Nanoparticle-Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes for Metastatic Breast Cancer: A Meta-Analysis. Sci Rep (2020) 10:530. doi: 10.1038/s41598-019-57380-0

23. Louage B, De Wever O, Hennink WE, De Geest BG. Developments and Age-Related Changes in Nanoparticle Albumin-Bound Paclitaxel Pharmacokinetics and Pharmacodynamics: Influence of Chronological Age. J Oncol Pharm Pract (2015) 20:37–44. doi: 10.1177/14740338.2014.910193

24. Crombag MBS, Dorlo TPC, van der Pan E, van Straten A, van der Pan E, van Straten A, et al. On the Clinical Pharmacokinetics of Paclitaxel in Cancer Patients: The COSTANza Study. Clinicoecon Outcomes Res (2015) 7:249–56. doi: 10.1517/CEOR.S82194

25. Alqahtani FY, Aleanizy FS, EEl Tahir HM. Alkahtani and BT AlQuadeib. Docetaxel. Profiles Drug Subst Excep Relat Medit (2019) 44:205–38. doi: 10.1016/bs.podr.2018.11.001

26. Mehkhal TM, Markman M. Paclitaxel in Cancer Therapy. Expert Opin Pharmacother (2002) 3:755–66. doi: 10.1517/14656566.3.7.755

27. Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOtAX Study. J Clin Oncol (2008) 26:5269–74. doi: 10.1200/JCO.2008.17.3146

28. Engels FK, Mathot RA, Verweij J. Alternative Drug Formulations of Docetaxel: A Review. Anticancer Drugs (2007) 18:985–1003. doi: 10.1097/COD.0b013e3281013338

29. Strauss SJ, Seddon B, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and Docetaxel Versus Doxorubicin as First-Line Treatment in Previously Untreated Advanced Unresectable or Metastatic Soft-Tissue Sarcomas (GeDDiS): A Randomised Controlled Phase 3 Trial. Lancet Oncol (2017) 18:1397–410. doi: 10.1016/S1470-2045(17)30622-8

30. Xu J, Guo W, Xie L. Combination of Gemcitabine and Docetaxel: A Regimen Overestimated in Refractory Metastatic Osteosarcoma? BMC Cancer (2018) 18:987. doi: 10.1186/s12885-018-4872-x

31. Sofias AM, Dunne M, Storm G, Allen C. The Battle of “Nano” Paclitaxel. Adv Drug Deliv Rev (2017) 122:20–30. doi: 10.1016/j.addr.2017.02.003

32. Kudlowitz D, Muggia F. Clinical Features of Taxane Neuropathy. Anticancer Drugs (2014) 25:495–501. doi: 10.1097/CAD.0000000000000051

33. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly Nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial. J Clin Oncol (2012) 30:2055–62. doi: 10.1200/JCO.2011.39.5848

34. Desai N, Trieu V, Yao Z, Louie C, Li S, Yang A, et al. Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared With Cremophor-Based Paclitaxel. Clin Cancer Res (2006) 12:1317–24. doi: 10.1158/1078-0432.CCR-05-1634

35. Viudez A, Ramirez N, Hernandez-Garcia I, Carvalho FL, Vera R, Hidalgo M. Nab-Paclitaxel: A Flattering Facelift. Crit Rev Oncol Hematol (2014) 92:666–80. doi: 10.1016/j.critrevonc.2014.06.001

36. Kudlowitz D, Muggia F. Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel): Extending Its Indications. Drug Des Devel Ther (2019) 13:531–7. doi: 10.2147/DDDT.S88023

37. Parsi A, Palluzzi E, Cortellini A, Sidoni T, Caccioclore V, Lanfuoti Baldi P, et al. First-Line Carboplatin/Nab-Paclitaxel in Advanced Ovarian Cancer Patients, After Hypersensitivity Reaction to Solvent-Based Taxanes: A Single-Institution Experience. Clin Transl Oncol (2020) 22:158–62. doi: 10.1007/s12094-019-2122-x

38. Takashima A, Shitara K, Fujitani K, Koeda K, Hara H, Nakayama N, et al. Peripheral Metastasis as a Predictive Factor for Nab-Paclitaxel in Patients With Pretreated Advanced Gastric Cancer: An Exploratory Analysis of the Phase III ABSOLUTE Trial. Gastric Cancer (2019) 22:155–63. doi: 10.1007/s10120-018-0838-6
Tian and Yao
Nab-Paclitaxel for Sarcomas

50. Sahai V, Catalan Pj, zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, et al. Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol (2018) 4:1707–12. doi: 10.1001/jamaoncol.2018.3277

51. Wang HY, Yao ZH, Tang H, Zhao Y, Zhang XS, Yao SN, et al. Weekly Nanoparticle Albumin-Bound Paclitaxel in Combination With Cisplatin Versus Weekly Solvent-Based Paclitaxel Plus Cisplatin as First-Line Therapy in Chinese Patients With Advanced Esophagopharyngeal Squamous Cell Carcinoma. Onco Targets Ther (2016) 9:5663–9. doi: 10.2147/OTST.S108580

52. Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, et al. Nab-Paclitaxel Versus Solvent-Based Paclitaxel in Patients With Previously Treated Advanced Gastric Cancer (ABSOLUTE): An Open-Label, Randomised, non-Inferiority, Phase 3 Trial. Lancet Gastroenterol Hepatol (2017) 2:277–87. doi: 10.1016/S2468-1253(16)30219-9

53. Ley J, Wildes TM, Daly K, Ooppelt P, Adkins D. Clinical Benefit

54. Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, et al. Randomized Phase II Study to Determine the Optimal Dose of 3-Week Cycle Nab-Paclitaxel in Patients With Metastatic Breast Cancer. Breast Cancer (2021) 29:131–43. doi: 10.1016/j.breast.2020.12.002

55. Houghton PJ, Kumasheva RT, Kolb EA, Gorilick R, Maris JM, Wu J, et al. Initial Testing (Stage 1) of the Tubulin Binding Agent Nanoparticle Albumin-Bound (Nab) Paclitaxel (Abraxane(R)) by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2015) 62:1214–21. doi: 10.1002/pbc.23547

56. Metts JL, Alazraki AL, Clark D, Amankwah EK, Wasilewski-Masker KJ, Metts JL, et al. Randomised Phase II Study of Weekly Nab-Paclitaxel Based Paclitaxel in Paediatric Patients With Recurrent/Refractory Solid Tumours: A Collaboration With Innovative Therapies for Children With Cancer. Eur J Cancer (2018) 106:27–34. doi: 10.1016/j.ejca.2018.05.002

57. Higuchi T, Kawaguchi K, Miyake K, Oshiro H, Zhang Z, Razmjooei S, et al. The Combination of Gemcitabine and Nab-Paclitaxel as a Novel Effective Treatment Strategy for Undifferentiated Soft-Tissue Sarcoma in a Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model. BioMed Pharmacother (2019) 111:835–40. doi: 10.1016/j.biopha.2018.12.110

58. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase II Trial of NaBPaclitaxel in Women With Breast Cancer. Atezolizumab for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer. Ann Oncol (2021) 32:994–1004. doi: 10.1016/j.annonc.2021.05.081

59. Dharana P, Abraham VG, O’Dea A, Nye L, Mayer I, Pathak HB, et al. Clinical and Biomarker Results From Phase I/II Study of PFS3 Inhibitor Alpelisib Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. Clin Cancer Res (2021) 27:3896–904. doi: 10.1158/1078-0432.CCR-20-4879

60. Taira N, Kashiwabara K, Tsurutani J, Kitada M, Takahashi M, Kato H, et al. Quality of Life in a Randomized Phase II Study to Determine the Optimal Dose of 3-Week Cycle Nab-Paclitaxel in Patients With Metastatic Breast Cancer. Breast Cancer (2021) 29:131–43. doi: 10.1016/j.breast.2020.12.002

61. Brufsky A. Nab-Paclitaxel for the Treatment of Breast Cancer: An Update

62. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. Ann Oncol (2013) 24:314–21. doi: 10.1093/annonc/mds461

63. Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, et al. A Phase II Randomised Comparison of Nab-Paclitaxel Plus Gemcitabine Versus Weekly Nab-Paclitaxel in Patients With Triple-Negative Breast Cancer. Oncologist (2021) 26:838–92. doi: 10.1002/onco.13574

64. Socinski MA, Langer CJ, Okamoto I, Hon JK, Hirsh V, Dakhil SR, et al. Safety and Efficacy of Weekly Nab-(R)-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Elderly Patients With Advanced non-Small-Cell Lung Cancer. Ann Oncol (2015) 26:929–37. doi: 10.1093/annonc/mdv235

65. Gajra A, Karim NA, Mulford DA, Villaruz LC, Matrana MR, Ali HY, et al. Nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2. Front Oncol (2018) 8:253. doi: 10.3389/fonc.2018.00253

66. Assahina H, Osumi S, Takamura K, Harada T, Harada M, Yokouchi H, et al. A Prospective Phase II Study of Carboplatin and Nab-Paclitaxel in Patients With Advanced Non-Small-Cell Lung Cancer and Concomitant Intersitial Lung Disease (HOT1302). Lung Cancer (2019) 138:65–71. doi: 10.1016/j.lungcan.2019.09.020

67. Liu Z, Wei Z, Hu Y, Gao F, Hao L, Fang P, et al. A Phase II Open-Label Clinical Study of Comparing Nab-Paclitaxel With Pemetrexed as Second-Line Chemotherapy for Patients With Stage IIIIB/IV non-Small-Cell Lung Cancer. Med Oncol (2015) 32:216. doi: 10.1007/s12032-015-0660-5

68. Wang Z, Huang C, Yang JL, Song Y, Cheng Y, Chen GY, et al. A Randomised Phase II Clinical Trial of Nab-Paclitaxel and Carboplatin Compared With Gemcitabine and Carboplatin as First-Line Therapy in Advanced Squamous Cell Lung Carcinoma (C-Tong1002). Eur J Cancer (2019) 109:183–91. doi: 10.1016/j.ejca.2019.01.007

69. Kawashima Y, Harada T, Fujita Y, Nakagawa T, Watanabe K, Morikawa N, et al. Randomized Phase II Trial of Carboplatin + Nab-Paclitaxel Versus Cisplatin + Gemcitabine for Chemotherapy-Naive Squamous Cell Carcinoma: North Japan Lung Cancer Study Group 1302. Int J Clin Oncol (2021) 26:515–22. doi: 10.1007/s10147-020-01828-1

70. Yoneshima Y, Morita S, Ando M, Nakamura A, Iwasawa S, Yoshioka H, et al. Phase 3 Trial Comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC. J Thorac Oncol (2016) 11:1523–32. doi: 10.1016/j.jtho.2016.03.027

71. Tanaka H, Hasegawa Y, Makiguchi T, Okumura F, Tabe C, Shiratori T, et al. A Phase I/II Study of Bicalutamide and Nab-Paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced
Tian and Yao

Nab-Paclitaxel for Sarcomas

81. Wu K, Zhu L, Wang J, Pan K, Wang B, Li X, et al. A Phase II Study of Concurrent Nab-Paclitaxel/Carboplatin Combined With Thoracic Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer. Oncologist (2020) 25:475–89. doi: 10.1634/theoncologist.2019-0746

82. Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, et al. Neoadjuvant Pembrolizumab Chemotherapy for the Treatment of Stage IIIA-IIIB Resectable Lung Squamous Cell Carcinoma. J Thorac Dis (2021) 13:1760–8. doi: 10.21037/jtd-21-103

83. Shen D, Wang J, Wu J, Chen S, Li J, Liu J, et al. Neoadjuvant Pembrolizumab Chemotherapy for the Treatment of Stage IIIA-IIIB Resectable Lung Squamous Cell Carcinoma. J Thorac Dis (2021) 13:1760–8. doi: 10.21037/jtd-21-103

84. Wang J, Li J, Cai L, Chen S, Jiang Y. The Safety and Efficacy of Neoadjuvant Programmed Death 1 Inhibitor Therapy With Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer. Ann Trans Med (2021) 9(6):486. doi: 10.21037/amt-21-670

85. Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, et al. Tidelixizumab Plus Chemotherapy vs Chemotherapy Alone as First-Line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol (2021) 7:709–17. doi: 10.1001/jamaoncol.2020.3066

86. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Updated Survival Data for a Phase II/III Study of Carboplatin Plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer. Oncologist (2020) 25:475–89. doi: 10.1634/theoncologist.2019-0746

87. Wu K, Zhu L, Wang J, Pan K, Wang B, Li X, et al. A Phase II Study of Concurrent Nab-Paclitaxel/Carboplatin Combined With Thoracic Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer. J Thorac Dis (2019) 11:4529–37. doi: 10.21037/jtd.2019.10.81

88. Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, et al. Neoadjuvant Pembrolizumab and Concurrent Radiotherapy in Locally Advanced Squamous Cell Lung Cancer: An Open-Label, Multicentre, Single-Arm, Phase 2 Trial. Lancet Oncol (2020) 21:786–95. doi: 10.1016/s1470-2045(20)304-10-0

89. Riedl JM, Posch F, Horvath L, Gantschnigg A, Renneberg F, Schwarzenbacher E, et al. Gemcitabine/nab-Paclitaxel Versus FOLFIRINOX for Palliative First-Line Treatment of Advanced Pancreatic Cancer: A Propensity Score Analysis. Eur J Cancer (2021) 151:3–13. doi: 10.1016/j.ejca.2021.03.040

90. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, et al. Updated Survival Data for a Phase I/II Study of Carboplatin Plus Nab-Paclitaxel Followed by FOLFIRINOX Induction Chemotherapy in Locally Advanced Pancreatic Cancer (NEOLAP-AIO-PAK-0113): A Multicentre, Randomised, Phase 2 Trial. Lancet Gastroenterol Hepatol (2020) 5:285–94. doi: 10.1016/s2468-1253(19)30327-9

91. Ko YJ, Canil CM, Mukherjee SD, Winquist E, Elser C, Eisen A, et al. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma. Ann Surg (2020) 272:481–9. doi: 10.1097/SLA.0000000000004155

92. Hare EM, Del Vecchio M, Brown MP, Kefford R, Loquiag C, Testoni A, et al. A Randomized, Controlled Phase III Trial of Nab-Paclitaxel Versus Dacarbazine in Chemotherapy-Naive Patients With Metastatic Melanoma. Ann Oncol (2015) 26:2627–74. doi: 10.1093/annonc/mdv324

93. Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, et al. Phase II Evaluation of Nanoparticle Albumin-Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer. J Clin Oncol (2009) 27:1426–31. doi: 10.1200/JCO.2008.18.0089

94. Watson S, de la Fouchardiere C, Kim S, Cohen R, Bachet JB, Tourignand C, et al. Oxaliplatin, 5-Fluorouracil and Nab-Paclitaxel as Perioperative Regimen in Patients With Resectable Gastric Adenocarcinoma: A GERCOR Phase II Study (FOXGAST). Eur J Cancer (2019) 107:46–52. doi: 10.1016/j.ejca.2018.11.006

95. Spiteri LE, Boasberg P, O’Day S, Hamid O, Cruickshank S, Mesko S, et al. Phase II Study of Nab-Paclitaxel and Bevacizumab as First-Line Therapy for Patients With Unresectable Stage III and IV Melanoma. Am J Clin Oncol (2015) 38:61–7. doi: 10.1097/COC.0b013e318287bbae

96. Giannatempo P, Raggi D, Marandino I, Bandini M, Fare E, Calareso G, et al. Pembrolizumab and Nab-Paclitaxel as Salvage Therapy for Platinum-Treated, Locally Advanced, or Metastatic Urothelial Carcinoma: Interim Results of the Open-Label, Single-Arm, Phase II PEANUT Study. Ann Oncol (2020) 31:1764–72. doi: 10.1016/j.annonc.2020.09.012

97. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolf RA, et al. Gemcitabine, Cisplatin, and Nab-Paclitaxel for the Treatment of Advanced
Biliary Tract Cancers: A Phase 2 Clinical Trial. *JAMA Oncol* (2019) 5:824–30. doi: 10.1001/jamaoncol.2019.0270

109. von Mehren M, Kane JM, Bui MM, Cho Y, Connely M, Dry S, et al. NCCN Guidelines Insights: Soft Tissue Sarcoma. Version 1.2021. *J Natl Compr Canc Netw* (2020) 18:1604–12. doi: 10.6004/jnccn.2020.0058

110. Ni. Update M. And Interpretation of 2021 National Comprehensive Cancer Guidelines Insights: Soft Tissue Sarcoma. Version 1.2021. *J Natl Compr Canc Netw* (2020) 18:1604–12. doi: 10.6004/jnccn.2020.0058

111. Casper ES, Waltzman RJ, Schwartz GK, Sugarman A, Pfister D, Ison D, et al. Phase II Trial of Paclitaxel in Patients With Soft-Tissue Sarcoma. *Cancer Invest* (1998) 16:442–6. doi: 10.3109/07357909809011697

112. Frezza AM, Ravi V, Lo Vullo S, Vincenzi B, Tolomeo F, Chen TW, et al. Systemic Therapies in Advanced Epithelioid Haemangioendothelioma: A Retrospective International Case Series From the World Sarcoma Network and a Review of Literature. *Cancer Med* (2021) 10:2645–59. doi: 10.1002/cam4.3807

113. Chen TW, Pang A, Puhaindran ME, Maw MM, Loong HH, Siuiranpong V, et al. The Treatment Landscape of Advanced Angiosarcoma in Asia-A Multi-National Collaboration From the Asian Sarcoma Consortium. *Cancer Sci* (2021) 112:1095–104. doi: 10.1111/cas.14793

114. Pink D, Andreou D, Bauer S, Brodowicz T, Kasper B, Reichardt P, et al. Treatment of Angiosarcoma With Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient(R)) in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06). *Cancers (Basel)* (2021) 13: doi: 10.3390/cancers13061223

115. Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoesel R, et al. Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *J Clin Oncol* (2000) 18:2081–6. doi: 10.1200/JCO.2000.18.10.2081

116. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, et al. The Treatment Landscape of Advanced Angiosarcoma in Asia-A Multi-National Collaboration From the Asian Sarcoma Consortium. *Cancer Sci* (2021) 112:1095–104. doi: 10.1111/cas.14793

117. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. A Phase Ib/Ii Study to Assess the Safety and Efficacy of Weekly Nab-Paclitaxel in Paediatric Patients With Recurrent or Refractory Solid Tumours: A Collaboration With the European Innovative Therapies for Children With Cancer Network. *Eur J Cancer* (2020) 135:89–97. doi: 10.1016/j.ejca.2020.04.031

118. Munhoz RR, D, d, Andreou D, Bauer S, Brodowicz T, Kasper B, Reichardt P, et al. Treatment of Angiosarcoma With Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient(R)) in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06). *Cancers (Basel)* (2021) 13: doi: 10.3390/cancers13061223

119. Kikuchi Y, Nishikawa Y, Amanuma M, Kishimoto Y, Takuma K, Wakayama M, et al. Successful Treatment of Advanced Pancreatic Leiomyosarcoma Treated With Gemcitabine Plus Nab-Paclitaxel: A Case Report and Literature Review. *Int Cancer Conf J* (2021) 10:63–7. doi: 10.1007/s13691-020-00452-0

120. Pham LM, Poudel K, Ou W, Phung CD, Nguyen HT, Nguyen BL, et al. Combination Chemotherapeutic and Immune-Therapeutic Anticancer Approach via Anti-PD-L1 Antibody Conjugated Albumin Nanoparticles. *Int J Pharm* (2021) 605:120816. doi: 10.1016/j.ijpharm.2021.120816

121. Yang M, Li J, Gu P, Fan X. The Application of Nanoparticles in Cancer Immunotherapy: Targeting Tumor Microenvironment. *Bioact Mater* (2021) 6:1973–87. doi: 10.1016/j.bioactmat.2020.12.010

122. Chen Y, Liu R, Li C, Song Y, Liu G, Huang Q, et al. Nab-Paclitaxel Promotes the Cancer-Immunity Cycle as a Potential Immunomodulator. *Am J Cancer Res* (2021) 11:3445–60.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Tian and Yao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.